Key Takeaways INSP reported positive Inspire V data with enhanced safety and better patient adherence.INSP's trials showed 20% shorter surgical times and superior AHI improvement versus Inspire IV.INSP's U.S. release confirmed efficient implantation, stable therapy use and no serious adverse events. Inspire Medical Systems (INSP) recently unveiled promising clinical data from its Inspire V system at the ISSS and AAO-HNS meetings, showcasing strong safety, enhanced respiratory sensing and improved patient ad ...

MINNEAPOLIS, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today published Inspire V clinical outcomes data from its Singapore clinical study as well as the Company’s limited market release in the United States including single site experience at two leading centers. These data will be presented at ...